JPIAMR supports research projects and networks that enable researchers to collaborate across national and scientific borders to find new treatments, solutions and methods to tackle AMR. It supports a large portfolio from 20 therapeutic candidates in the pipeline, to new knowledge on selection and transmission dynamics of AMR in a One Health context, the design of new interventions or new surveillance studies, standards and protocols.

Projects

Projects

JPIAMR supports research projects and networks that enable researchers to collaborate across national and scientific borders to find new treatments, solutions and methods to tackle AMR. It supports a large portfolio from 20 therapeutic candidates in the pipeline, to new knowledge on selection and transmission dynamics of AMR in a One Health context, the design of new interventions or new surveillance studies, standards and protocols.

Supported JPIAMR projects and networks

​JPIAMR has coordinated 10 transnational joint calls till date supporting 61 projects and 38 networks with over 1170 researchers by investing 80 million Euros within the six priority areas of the shared JPIAMR Strategic Research and Innovation Agenda (SRIA) – therapeutics, diagnostics, surveillance, transmission, environment and interventions with a One Health approach.

Explore the JPIAMR project dashboard that presents interactive data on projects and networks supported under the various calls coordinated by the JPIAMR.

Click on the titles below for more information on the research activities and outcomes of the projects and the networks supported under the JPIAMR framework.

The JPIAMR six Priority topics are:

Transmission  Environment  Interventions  Therapeutics  Diagnostics  Surveillance

Network T&CM alternatives for antibiotics worldwide: Global Initiative for Traditional Solutions to Antimicrobial Resistance (GIFTS-AMR)

Traditional and Complementary Medicine (T&CM) is often used in both animal and human healthcare and may contribute to reducing inappropriate antibiotic use (e.g. as part of delayed prescription strategies (human healthcare) or as alternative prevention or treatment (e.g. for uncomplicated acute infections in both human and animal healthcare).

Sharing Research on AMR Network (SHARENET)

The threat of AMR is rising in low and middle income countries (LMIC). The French Alliance of Health Sciences Research Institution (AVIESAN) has recently established a small network for AMR research in partnership with LMIC scientists to strengthen local research expertise. The aim is to assist in the collection of relevant evidence to advise stakeholders and policymakers on suitable control strategies for AMR reduction that are tailored to the local situation and founded on local problematics. Countries initially involved are Cambodia, Madagascar, Ivory Coast and France.

Convergence in evaluation frameworks for integrated surveillance of AMR, CoEval-AMR PHASE 2

An integrated approach to surveillance spanning different sectors has been promoted by international organisations for more than a decade and constitutes a central recommendation of the WHO action plan on AMR. The objective of the CoEval-AMR Network is to develop consolidated guidance for evaluation that addresses the specific needs of integrated One Health surveillance systems for AMR and AMU.

GAP-ON€-2

The impact of antimicrobial resistance (AMR) is an almost invisible enemy, which slowly, but steadily has impacted society as a whole. Multi-, and/or pan-drug resistant strains have emerged, and have been spreading readily, causing deaths, disabilities and economic losses.